prostate cancer cell line pc3  (ATCC)

Journal: ACS Biomaterials Science & Engineering

Article Title: Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers

doi: 10.1021/acsbiomaterials.5c02175

Figure Lengend Snippet: Basal expression of MCT and MPC in PC3 and FaDu cells. Representative immunoblots (a) and densitometric quantification (d) of basal MCT1, MCT4, and MPC expressions in PC3 and FaDu cells. Representative immunoblots (b) and quantification (e) show MCT1, MCT4, and MPC expression in PC3 cells under normoxia (21% O 2 ) or hypoxia (0.5% O 2 ), while representative immunoblots (c) and quantification (f) show the same proteins in FaDu cells under these conditions. Data represent the mean ± SD from three independent experiments. Statistical significance was determined using a two-tailed Student’s t test.

Article Snippet: FaDu (HPV(−) HNSCC) and PC3 (prostate cancer) cell lines were sourced from the American Type Culture Collection (ATCC) and routinely tested for mycoplasma contamination (Lonza).

Techniques: Expressing, Western Blot, Two Tailed Test

Journal: ACS Biomaterials Science & Engineering

Article Title: Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers

doi: 10.1021/acsbiomaterials.5c02175

Figure Lengend Snippet: Inhibitors of lactate metabolism influence tumor cell growth depending on substrate availability (lactate or glucose). PC3 and FaDu cells were treated with AZD3965 (1 μM), syrosingopine (10 μM), 7ACC2 (10 μM), or in combination in complete media supplemented with either lactate or glucose for 72 h under normoxic (a–b) and hypoxic (c–d) conditions. Data represent mean ± SD from three independent replicates. Statistical significance was assessed using one-way ANOVA with Tukey’s posthoc test.

Article Snippet: FaDu (HPV(−) HNSCC) and PC3 (prostate cancer) cell lines were sourced from the American Type Culture Collection (ATCC) and routinely tested for mycoplasma contamination (Lonza).

Techniques:

Journal: ACS Biomaterials Science & Engineering

Article Title: Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers

doi: 10.1021/acsbiomaterials.5c02175

Figure Lengend Snippet: Inhibiting lactate metabolism sensitizes tumor cells to radiation under both normoxic and hypoxic conditions. Clonogenic survival curves for PC3 (a, b) and FaDu (c, d) cells treated with AZD3965 (1 μM), syrosingopine (10 μM), 7ACC2 (10 μM), or combinations for 24 h under normoxia (a, c21% O 2 ) or hypoxia (b, d0.5% O 2 ). Data represent the mean ± SD of three independent experiments. Statistical significance was assessed using two-way ANOVA with Tukey’s multiple comparison test.

Article Snippet: FaDu (HPV(−) HNSCC) and PC3 (prostate cancer) cell lines were sourced from the American Type Culture Collection (ATCC) and routinely tested for mycoplasma contamination (Lonza).

Techniques: Comparison

Journal: ACS Biomaterials Science & Engineering

Article Title: Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers

doi: 10.1021/acsbiomaterials.5c02175

Figure Lengend Snippet: 7ACC2 inhibition of MPC reduces oxygen consumption and TCA cycle activity. Bioenergetic profile of PC3 (a, b) and FaDu (c, d) cells treated with 7ACC2. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were monitored at 37 °C for 2 h, reported as percentage change over baseline following treatment. Data are presented as mean ± SD ( n = 3 per treatment group). Relative levels of succinate were observed in PC3 (e) and FaDu (f) cells after 7ACC2 (10 μM) treatment for 24 h. Data derived from three independent replicates, presented as mean ± SD. Statistical differences determined by one-way ANOVA with a Tukey multiple comparison test.

Article Snippet: FaDu (HPV(−) HNSCC) and PC3 (prostate cancer) cell lines were sourced from the American Type Culture Collection (ATCC) and routinely tested for mycoplasma contamination (Lonza).

Techniques: Inhibition, Activity Assay, Derivative Assay, Comparison

Journal: Cancer Pathogenesis and Therapy

Article Title: Neuroendocrine prostate cancer (NEPC)-associated CEP55 promotes cisplatin resistance in prostate cancer by regulating CDK1 phosphorylation

doi: 10.1016/j.cpt.2025.06.008

Figure Lengend Snippet: CEP55 plays an oncogenic role in prostate cancer. (A) The transcript levels of CEP55 in 22 paired prostate tumors and adjacent tissues. (B) The protein level of CEP55 in 4 paired prostate tumors and adjacent tissues. (C) The immunohistochemical picture of 2 paired prostate tumors and adjacent tissues. The scale on the lower left corner represented 100 μm. (D) The protein level of CEP55 in Lncap, C4-2, DU145, and PC3 cells. (E) The translation validation after CEP55 overexpression and knockdown in PC3 cells. (F–K) Cell viability, clone formation, migration, and analysis about DU145, PC3 cells after CEP55 knockdown (F–H) and overexpression (I–K). The scale on the lower right corner represented 200 μm. (L) Subcutaneous tumor formation in nude mice after injecting 1×10 7 shNC or sh CEP55 -1 PC3 cells. The tumor volume was measured every week. Data are represented as mean ± SD. (M) The protein levels of CEP55 , CHGA , NSE , and SYP after CEP55 overexpression in DU145, PC3 cells. (N) The protein levels of CEP55 , CHGA , NSE , and SYP after CEP55 knockdown in PC3 cells. GAPDH acted as an internal reference. ns-not significant difference, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001. CEP55 : Centrosomal protein 55; sh CEP55 : Knockdown of CEP5 5 by shRNA; oeCEP55: Overexpression of CEP55; si CEP55 : Small interfering RNA targeting CEP55 ; A 450 : Optical Density at 450 nm; CHGA : Chromogranin A gene; NSE : Neuron-Specific Enolase; SYP : Synaptophysin.

Article Snippet: Prostate cancer cell lines PC3, DU145, C4-2, LNcap, and human embryonic kidney cell line HEK293T were purchased from the American Type Culture Collection (ATCC).

Techniques: Immunohistochemical staining, Biomarker Discovery, Over Expression, Knockdown, Migration, shRNA, Small Interfering RNA

Journal: Cancer Pathogenesis and Therapy

Article Title: Neuroendocrine prostate cancer (NEPC)-associated CEP55 promotes cisplatin resistance in prostate cancer by regulating CDK1 phosphorylation

doi: 10.1016/j.cpt.2025.06.008

Figure Lengend Snippet: CEP55 mediated cisplatin resistance via CDK1 phosphorylation at Tyr15 in prostate cancer cells. (A) Relative cell survival rate after CEP55 knockdown and overexpression in DU145 and PC3 cells treated with 1 μg/mL cisplatin for 24 h or not. (B–D) GSEA, GO, and KEGG analyses after being divided into low- and high- CEP55 expression groups from the TCGA database. (E) KEGG analysis of RNA sequencing in shNC and sh CEP55 -2 PC3 cells. (F) Cell cycle assessment of in shNC, sh CEP55 DU145, and PC3 cells treated with 1 μg/mL cisplatin for 24 h. (G) Analysis of co-immunoprecipitation between CEP55 and phospho-CDK1 Tyr15 in DU145, PC3 cells. The IgG group acted as a negative control. (H) The protein level of CEP55 , CDK1, and phospho-CDK1 Tyr15 in shNC, sh CEP55 -2 DU145 cells treated with 1 μg/mL cisplatin for 0, 8, 16, and 24 h. Data are represented as mean ± SD. ns-not significant difference, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001. CEP55 : Centrosomal protein 55; sh CEP55 : Knockdown of CEP5 5 by shRNA; oeCEP55: Overexpression of CEP55; si CEP55 : Small interfering RNA targeting CEP55 ; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSEA: Gene Set Enrichment Analysis; CDK1: Cyclin-dependent kinase 1; Tyr15: Tyrosine 15.

Article Snippet: Prostate cancer cell lines PC3, DU145, C4-2, LNcap, and human embryonic kidney cell line HEK293T were purchased from the American Type Culture Collection (ATCC).

Techniques: Phospho-proteomics, Knockdown, Over Expression, Expressing, RNA Sequencing, Immunoprecipitation, Negative Control, shRNA, Small Interfering RNA